INHRR in Venezuela: Legal Status and Technical Testing Role
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The Rafael Rangel National Institute of Hygiene (Instituto Nacional de Higiene Rafael Rangel, INHRR) was created on October 17, 1938, and its organizational regulation is published in Gaceta Oficial N° 4.529 of February 10, 1993. INHRR is a technical testing and evaluation body, not a registration authority: it does not issue sanitary registration certificates.
Clarifying this has immediate project value. Treating INHRR as an approving authority leads a company to invest excessive expectation in the testing stage while under-resourcing the actual approval stage. The correct positioning is the opposite: INHRR provides testing and evaluation conclusions, and SACS takes the registration decision on the basis of the material before it, including those conclusions.
The consequence for scheduling is concrete. Testing and review are governed by different institutions with different queues, different internal priorities and different clocks, so they cannot be treated as one waiting period. A plan that assumes the file moves forward automatically once testing is complete will lose visibility exactly at the moment when the file has changed hands and no party is chasing it.
It is also worth being precise about what a test conclusion can and cannot do. It can establish that a sample met a defined specification under defined conditions, and it can carry substantial weight in review because the issuing body is the national reference institution. It cannot establish that the product is approved, that the labeling is acceptable, or that the dossier is complete. Those remain decisions of SACS, taken on the whole file rather than on the laboratory output alone.
2. Legal basis
| Instrument | Reference number | Publication date | Article / key point |
|---|---|---|---|
| Reglamento del Decreto de Creación del INHRR | Gaceta Oficial N° 4.529 | February 10, 1993 | Organizational regulation of INHRR |
| Fact of creation of INHRR | — | October 17, 1938 | Date on which the institution was created |
| Ley Orgánica de Salud (Organic Health Law) | Gaceta Oficial N° 36.579 | November 11, 1998 | Superior legal framework |
| Reglamento Orgánico del MPPS | Gaceta Oficial N° 38.591 | December 26, 2006 | Organizational relationship placing INHRR under the Ministry of Health |
3. Expert insights
Insight 1: the mandate of INHRR is broad, and device testing is only one part of it. Its activities cover sanitary control and testing for product registration, diagnostics and epidemiological surveillance in bacteriology, virology and mycology, teaching and applied research, and the production of biological products and reagents. This breadth means that testing slots are exposed to being displaced by public health tasks, which is one structural reason why project timelines in Venezuela are difficult to predict with precision.
Insight 2: the status of national reference institution determines the weight of a test conclusion. As the national reference body, conclusions issued by INHRR carry substantial weight in the review performed by SACS. The converse is equally true: a product that has no testing pathway recognized by INHRR enters review without strong technical support, and the gaps are then filled by observations rather than by evidence.
Insight 3: local testing requirements and the fit of imported products are a recurring problem. For imported devices, additional testing or verification in a laboratory recognized in Venezuela may be required, particularly on electrical safety, electromagnetic compatibility and performance parameters. Differences in local grid conditions and voltage frequency are precisely the part that a foreign test report may not fully cover, a point developed further in Article 27.
The combined effect is that testing should be planned as a work package with its own logic rather than as a line item in the approval timeline. It has its own entry conditions, its own sample logistics and its own output format, and each of those can stop the package independently of anything happening in the review file.
That independence cuts both ways. It means testing can run in parallel with dossier preparation and shorten the total duration, and it also means a failure in sample logistics or in report formatting delays the project without producing any signal in the review file. Treating testing as a subcontract with its own deliverables, its own acceptance criteria and its own owner is the arrangement that captures the first effect without being exposed to the second.
The practical question to settle early is therefore not whether the product needs testing, but what evidence the review will accept in place of testing where local testing is not triggered. That question is answered by the intake window, and the answer determines whether the project budget carries a laboratory line at all.
4. Practical recommendations
- Reserve a separate block for testing in the project schedule. Do not merge it into the review waiting period, because the two are driven by different institutions and run on different clocks.
- Confirm in advance whether the product triggers a local testing requirement, and whether the testing must be performed at INHRR or at a laboratory recognized by it.
- Import test samples through the non-commercial sample channel, ensuring that the quantity, nature and value do not constitute a commercial purpose, as examined in Article 19.
- The language and format of test reports must meet the submission requirements of SACS, and translated versions must be retained alongside the originals so that they can be produced on request during verification.
5. Verification checklist
- □ Confirmed whether the product triggers a local testing requirement in Venezuela
- □ Confirmed whether the testing body is INHRR or a laboratory recognized by it
- □ Confirmed that the test scope covers electrical safety and EMC under local grid conditions
- □ Confirmed that the import channel and documents for test samples are prepared as non-commercial samples
- □ Confirmed that the validity of the test report covers the expected review period
Regulatory information verified as of October 29, 2026.
For a Venezuela market-entry feasibility assessment covering your specific product, contact the GRZAN regulatory team. GRZAN supports manufacturers, importers and authorized representatives with device registration in Venezuela: clarifying the boundary between testing and approval, arranging local test scopes, preparing non-commercial sample imports, and keeping the review file moving while testing runs in parallel. Reach us at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us